Genzyme Corporation and Ilex Oncology, Inc., In the Matter of

Last Updated:
In the Matter of Genzyme Corporation and Ilex Oncology, Inc.
FTC Matter/File Number:


Enforcement Type:

Part 2 Consents

Case Summary

A consent order allowed Genzyme’s acquisition of ILEX Oncology, Inc., but requires the companies to divest certain assets in the market for solid organ transplant acute therapy drugs. Specifically, Genzyme is required to divest all contractual rights related to ILEX’s Campath®, an immunosuppressant antibody used in solid organ transplants to Schering AG.